Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action

Ding Qian; Li Zhen; Liu Bin; Ling LiPing; Zhang ChunQing

doi:10.3969/j.issn.1001-5256.2017.03.018

Issue 3

Mar. 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(3): 485-491

PDF( 2173 KB)

Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action

DOI: 10.3969/j.issn.1001-5256.2017.03.018

Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University

Research funding:

Published Date: 2017-03-20

Abstract

Abstract

Objective To investigate the effect of carvedilol on the migration, invasion and fibrosis of human hepatic stellate cells, as well as related signaling pathways and mechanisms.Methods Human hepatic stellate cell line LX-2 was treated with different concentrations of carvedilol (0, 1, 2, 5, and 10 μmol/L, and platelet-derived growth factor-BB (PDGF-BB) was added to activate the cells.CCK-8 assay was used to measure cell proliferation, wound healing assay was used to measure migration, Transwell chamber assay was used to measure invasion, and Western blot and real-time PCR were used to measure the protein and mRNA expression of fibrosis markers and pathway proteins.The cells were divided into blank control group, PDGF-BB group (only PDGF-BB was added) , and four carvedilol groups (with 1, 2, 5, or 10 μmol/L carvedilol, as well as PDGF-BB) .A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the Dunnett-t test was used for comparison between experimental groups and control group.Results Carvedilol inhibited the proliferation of LX-2 cells in a concentration-dependent manner, with a half-inhibitory concentration of28.42 μmol/L.Compared with the PDGF-BB group, the 10 μmol/L carvedilol group had significantly inhibited migration of LX-2 cells (59.780%±8.898% vs 17.270%±2.668%, t=4.576, P=0.010) .PDGF-BB increased the invasion of LX-2 cells, and carvedilol inhibited the invasion of LX-2 cells in a concentration-dependent manner;the invasion of LX-2 cells was reduced from 157.00%±10.52% to 85.15%±13.50% in the 2 μmol/L carvedilol group (t=4.198, P=0.014) , to 55.67%±9.54% in the 5 μmol/L carvedilol group (t=7.133, P<0.01) , and to 45.37%±10.70% in the 10 μmol/L carvedilol group (t=7.438, P<0.01) .The mRNA expression of type I collagen was reduced from 1.068±0.128 to 0.453±0.085 in the 5 μmol/L carvedilol group (t=3.997, P<0.05) and to 0.151±0.019 in the 10 μmol/L carvedilol group (t=7.091, P<0.01) .The mRNA expression of fibronectin was reduced from 1.285±0.042 to 0.879±0.063 in the 1 μmol/L carvedilol group (t=5.345, P<0.01) , to 0.768±0.010 in the 2 μmol/L carvedilol group (t=4.773, P<0.01) , to 0.742±0.117 in the 5 μmol/L carvedilol group (t=4.385, P=0.012) , and to 0.591±0.049 in the 10 μmol/L carvedilol group (t=10.76, P<0.01) .The expression of fibronectin was reduced from 2.103±0.414 to 0.739±0.132 in the 5 μmol/L carvedilol group (t=3.137, P=0.035) and to 0.600±0.114 in the 10 μmol/L carvedilol group (t=3.499, P=0.025) , and the expression of α-smooth muscle actin was reduced from 1.418±0.241 to 0.543±0.215 (t=2.710, P=0.035) and 0.343±0.118 (t=4.005, P <0.01) , respectively.Y751 phosphorylation was reduced from 2.309±0.181 to 1.278±0.304 in the 2 μmol/L carvedilol group (t=2.912, P=0.044) , to 0.555±0.038 in the 5 μmol/L carvedilol group (t=9.476, P<0.01) , and to 0.175±0.039 in the 10 μmol/L group (t=11.51, P<0.01) .Akt phosphorylation was reduced from 1.106±0.185 to 0.335±0.132 in the 5 μmol/L carvedilol group (t=3.386, P=0.015) and to 0.137±0.110 in the 10 μmol/L carvedilol group (t=4.494, P<0.01) .Conclusion Carvedilol can inhibit the proliferation, migration, invasion, and fibrosis of LX-2 cells induced by PDGF-BB, mainly by blocking the PDGF-BB/PDGFR-β/Akt signaling pathway.
- carvedilol,
- hepatic stellate cells,
- liver cirrhosis,
- platelet-derived growth factor

FullText(HTML)

References(24)

References

[1]LALEMAN W, NEVENS F.Cirrhotic portal hypertension:current and future medical therapy for primary and secondary prevention of variceal bleeding[J].Minerva Medica, 2006, 97 (4) :325-345.

[2]TRIPATHI D, HAYES P C.The role of carvedilol in the management of portal hypertension[J].Eur J Gastroenterol Hepatol, 2010, 22 (8) :905-911.

[3]LIANG CL, FAN XM.Effects of carvedilol on hepatic fibrosis[J].Chin J Gen Prac, 2010, 8 (10) :1211-1212. (in Chinese) 梁春丽, 樊晓明.卡维地洛抗肝纤维化的试验研究[J].中华全科医学, 2010, 8 (10) :1211-1212.

[4]LIANG CL, FAN XM, BU SR.Effects of carvedilol on proliferation and apoptosis of hepatic stellate cells[J].Chin Hepatol, 2012, 17 (10) :709-711. (in Chinese) 梁春丽, 樊晓明, 卜淑蕊.卡维地洛对肝星状细胞增殖与凋亡的影响[J].肝脏, 2012, 17 (10) :709-711.

[5]JIAO J, FRIEDMAN SL, ALOMAN C.Hepatic fibrosis[J].Curr Opin Gastroenterol, 2009, 25 (3) :223-229.

[6]QU K, HUANG Z, LIN T, et al.New insight into the anti-liver fibrosis effect of multitargeted tyrosine kinase inhibitors:from molecular target to clinical trials[J].Front Pharmacol, 2016, 6:300.

[7]LIU XJ, YANG L, MAO YQ, et al.Effects of the tyrosine protein kinase inhibitor genistein on the proliferation, activation of cultured rat hepatic stellate cells[J].World J Gastroenterol, 2002, 8 (4) :739-745.

[8]YOSHIJI H, NOGUCHI R, KURIYAMA S, et al.Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats[J].Am J Physiol Gastrointest Liver Physiol, 2005, 288 (5) :g907-g913.

[9]CHEN YX, LU CH, XIE WF, et al.Effects of ribozyme targeting platelet-derived growth factor receptor beta subunit gene on the proliferation and apoptosis of hepatic stellate cells in vitro[J].Chin Med J (Engl) , 2005, 118 (12) :982-988.

[10]IWAMOTO H, NAKAMUTA M, TADA S, et al.Platelet-derived growth factor receptor tyrosine kinase inhibitor AG1295 attenuates rat hepatic stellate cell growth[J].J Lab Clin Med, 2000, 135 (5) :406-412.

[11]BORKHAM-KAMPHORST E, STOLL D, GRESSNER AM, et al.Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis[J].Biochem Biophys Res Commun, 2004, 321 (2) :413-423.

[12]HANADA M, FENG J, HEMMINGS BA.Structure, regulation and function of PKB/AKT-a major therapeutic target[J].Biochim Biophys Acta, 2004, 1697 (1-2) :3-16.

[13]FRIEDMAN S L.Mechanisms of hepatic fibrogenesis[J].Gastroenterology, 2008, 134 (6) :1655-1669.

[14]LEE YA, WALLACE MC, FRIEDMAN SL.Pathobiology of liver fibrosis:a translational success story[J].Gut, 2015, 64 (5) :830-841.

[15]ALTOMARE DA, TESTA JR.Perturbations of the AKT signaling pathway in human cancer[J].Oncogene, 2005, 24 (50) :7455-7464.

[16]WANG Y, GAO J, ZHANG D, et al.New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis[J].J Hepatol, 2010, 53 (1) :132-144.

[17]de FRANCHIS R, BAVENO VI FACULTY.Expanding consensus in portal hypertension:report of the Baveno VI Consensus Workshop:stratifying risk and individualizing care for portal hypertension[J].J Hepatol, 2015, 63 (3) :743-752.

[18]OBEN JA, YANG S, LIN H, et al.Norepinephrine and neuropeptide Y promote proliferation and collagen gene expression of hepatic myofibroblastic stellate cells[J].Biochem Biophys Res Commun, 2003, 302 (4) :685-690.

[19]KOBAYASHI N, NAKANO S, MORI Y, et al.Betaxolol inhibits extracellular signal-regulated kinase and P70S6 kinase activities and gene expressions of platelet-derived growth factor A-chain and transforming growth factor-beta1 in Dahl salt-sensitive hypertensive rats[J].Hypertens Res, 2002, 25 (2) :211-219.

[20]WONG VY, LAPING NJ, NELSON AH, et al.Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression[J].Br J Pharmacol, 2001, 134 (5) :977-984.

[21]LOTZE U, HEINKE S, FRITZENWANGER M, et al.Carvedilol inhibits platelet-derived growth factor-induced signal transduction in human cardiac fibroblasts[J].J Cardiovasc Pharmacol, 2002, 39 (4) :576-589.

[22]HAMDY N, EL-DEMERDASH E.New therapeutic aspect for carvedilol:antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage[J].Toxicol Appl Pharmacol, 2012, 261 (3) :292-299.

[23]LIU J, TAKASE I, HAKUCHO A, et al.Carvedilol attenuates the progression of alcohol fatty liver disease in rats[J].Alcohol Clin Exp Res, 2012, 36 (9) :1587-1599.

[24]HAKUCHO A, LIU J, LIU X, et al.Carvedilol improves ethanolinduced liver injury via modifying the interaction between oxidative stress and sympathetic hyperactivity in rats[J].Hepatol Res, 2014, 44 (5) :560-570.

Relative Articles

[1]	Ru JIA, Pingping ZHANG, Yuan YUAN, Yiyang HU, Qin FENG. Differences and application value of plasma bile acids in tumors of the liver[J]. Journal of Clinical Hepatology, 2024, 40(10): 2042-2048. doi: 10.12449/JCH241018
[2]	Jun SONG, Lujia NI, Hanyu ZHANG, Xingzhao LI. Value of contrast-enhanced ultrasound combined with shear wave elastography in the diagnosis of benign and malignant liver tumors： A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(7): 1404-1410. doi: 10.12449/JCH240719
[3]	ZHANG ZhongLin, YUAN YuFeng. Key operating points of laparoscopic hepatectomy for liver tumor in difficult locations[J]. Journal of Clinical Hepatology, 2020, 36(12): 2663-2666. doi: 10.3969/j.issn.1001-5256.2020.12.006
[4]	Li ShanShan, Zhang Ke, Cheng ShuJie, Yang JiHong, Gao Feng, Li JingHua. Current status and future perspectives of the application of medical 3D visualization technology in accurate surgery of liver tumors[J]. Journal of Clinical Hepatology, 2019, 35(5): 1114-1117. doi: 10.3969/j.issn.1001-5256.2019.05.042
[5]	Xu LiLi, Mu JingJing, Zhang Tong, Tong MingHui. Imaging diagnosis of portal vein double branch malformation: A case report[J]. Journal of Clinical Hepatology, 2018, 34(9): 1982-1983. doi: 10.3969/j.issn.1001-5256.2018.09.031
[6]	Wang Yi. Role of imaging techniques in clinical research and practice on nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2307-2310. doi: 10.3969/j.issn.1001-5256.2017.12.010
[7]	Sun XueFeng, Yuan XinYu. Imaging diagnosis of liver tumors in children[J]. Journal of Clinical Hepatology, 2016, 32(12): 2282-2288. doi: 10.3969/j.issn.1001-5256.2016.12.011
[8]	Li JingHua, Cui ShiChang, Sun Jian, Fang Da, Du Ning, Zheng JiaSheng, Cui XiongWei. Relationship between tumor location and pain level in CT-guided percutaneous microwave ablation of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(6): 903-906. doi: 10.3969/j.issn.1001-5256.2015.06.018
[9]	Wang YiBin, Liao JinTang, Xie LuLu, Qi WenJun, Chen LuYang, Li YueYi. Predictive value of preoperative ultrasound examination for factors associated with early postoperative recurrence of hepatocellular carcinoma after surgical resection [J]. Journal of Clinical Hepatology, 2015, 31(12): 2061-2065. doi: 10.3969/j.issn.1001-5256.2015.12.018
[10]	Liu LingFeng, Lu HaiYing, Yu YanYan, Wu ChiHong, Tian XiuLan. A comparative study of FibroScan and B ultrasound in diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2014, 30(10): 1045-1049. doi: 10.3969/j.issn.1001-5256.2014.10.018
[11]	Ge MingGang, Zhang Wei, Zhu Yu. Application of contrast-enhanced ultrasound in hepatectomy for primary liver cancer: a report of 42 cases [J]. Journal of Clinical Hepatology, 2014, 30(3): 242-244. doi: 10.3969/j.issn.1001-5256.2014.03.011
[12]	Zhang QinQin, Chen Fei, Qiu ShaoDong. Diagnostic values of ultrasonography and CT for gallbladder adenomyomatosis: a comparative analysis[J]. Journal of Clinical Hepatology, 2014, 30(6): 543-545. doi: 10.3969/j.issn.1001-5256.2014.06.016
[13]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[14]	Wang Hui, Yang DongHong, Ma SuMei, Chen Fei. Contrast-enhanced ultrasound and contrast-enhanced CT diagnostic value of the AFP-negative hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2012, 28(4): 261-263+266.
[15]	Wang Zhen, Hua GuoMing, Xia CongYang. SCT diagnosis and pathological analysis of hepatic angiomyolipoma[J]. Journal of Clinical Hepatology, 2011, 27(9): 970-971.
[16]	Wang JiPing, Leng JiYan, Cui YaQiong, Zhang Li, Wang Yan. The diagnosis and clinical value of multi-slice spiral CT in children with common liver tumor[J]. Journal of Clinical Hepatology, 2011, 27(7): 718-721.
[17]	Wang BingLiang, Qiao NaiChun, Chen LaiRong, Sun Wei. Spiral CT in the diagnosis of liver cancer complicated with portal vein cavernous degeneration and its significance in interventional therapy [J]. Journal of Clinical Hepatology, 2010, 26(5): 540-542.
[18]	Wang Yan, Li BingShun, Wang JianBin. Study about ultrasonic and fibrosis parameters with diagnose of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2008, 24(1): 31-33.
[20]	Zhang XiaoHong, Zheng RongQin, Lu CuiRong, Chen Qing, Yang ShaoJi. Ultrasonography prediction of the portal hypertensive gastropathy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2004, 20(1): 30-31.

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	吴昊，郑欣，朱磊，杨冬. 以肝损害为主要表现的嗜酸粒细胞增多症1例报告. 临床肝胆病杂志. 2022(04): 883-885 . 本站查看
2.	范松松，张芳，杨立鹏，曹学峰，卢艳敏，张兴元. 慢性胆管炎伴间质黏液变性误诊为胆管癌1例报告. 临床肝胆病杂志. 2022(07): 1626-1628 . 本站查看
3.	麻芝英，杨显文. 16例IgG_4相关硬化性胆管炎患者的临床特点及诊治分析. 内科. 2022(03): 322-324 .
4.	杨显文，麻芝英. 以黄疸为首发表现不伴AIP的IgG4相关硬化性胆管炎1例. 中国医药导报. 2022(24): 175-178 .
5.	龚沁，张红星，陆敏丹，宛传丹，浦晓红. 血清免疫球蛋白G4在相关疾病中的分布特征与诊断价值. 实用检验医师杂志. 2022(04): 412-415 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2170) PDF downloads(439)

Inhibitory effect of carvedilol on human hepatic stellate cell activation and fibrosis induced by platelet-derived growth factor-BB and related mechanisms of action

DOI: 10.3969/j.issn.1001-5256.2017.03.018